AGP Executive Report
Last update: 10 hours agoRegulatory Pharma: Neuren Pharmaceuticals’ Rett syndrome drug Daybu (trofinetide) cleared a major hurdle after the EMA’s CHMP reversed course and issued a positive opinion, paving the way for a European Commission decision; if approved, it would be the first EU treatment for Rett neurobehavioral symptoms for patients aged five and older, with potential sales milestones and royalties for Neuren and partner Acadia. Regulatory Pharma: Merck (MSD) also won EU approval for Keytruda plus Padcev as a perioperative regimen for cisplatin-ineligible adults with resectable muscle-invasive bladder cancer, aiming to cut recurrence and death risk. Crypto & Finance (Liechtenstein): Bitcoin Suisse secured a MiCAR licence from Liechtenstein’s financial regulator, enabling regulated crypto services across selected EEA markets, while OpenPayd obtained MiCA authorization to expand stablecoin and custody services ahead of the July 1 deadline. Trade & Policy: Thailand pushed for more trade diversification, including an FTA path with EFTA (Switzerland, Liechtenstein, Norway, Iceland) and continued EU talks, as it seeks to reduce reliance on the US. Business & Legal: A court in Ontario allowed fraud claims to proceed against a Liechtenstein-based trustee, rejecting jurisdiction objections and keeping cross-border trust disputes in focus.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
